Table 1: Variables associated with increased risk of possible mobilization failure.

VariableMain references

AgeHosing et al., 2009 [84]
Kuittinen et al., 2004 [85]
Wuchter et al., 2010 [86]
Olivieri et al., 2012 [87]

Mobilization with G-CSF aloneHosing et al., 2009 [84]
Petit et al., 2002 [88]
Bensinger et al., 2009 [89]

Bone marrow infiltration by tumor cellsKuittinen et al., 2004 [85]
Demirer et al., 1996 [90]

Disease
 Lymphomas > myelomaPusic et al., 2008 [91]
 Chronic lymphocytic leukemiaJantunen et al., 2008 [92]
 Disease statusHaas et al., 1994 [93]
Wuchter et al., 2010 [86]
Bensinger et al., 2009 [89]

Previous myelotoxic chemotherapy Mohty and Ho, 2011 [69]
Gertz et al., 2010 [71]
Jantunen et al., 2008 [92]
Wuchter et al., 2010 [86]
Bensinger et al., 2009 [89]
Lysak et al., 2005 [94]
Laszlo et al., 2004 [95]
Popat et al., 2009 [96]

Previous extensive radiotherapy to BMBensinger et al., 1995 [70]
Haas et al., 1994 [93]
Sevilla et al., 2013 [97]
Demirer et al., 1996 [90]
Olivieri et al., 2012 [87]

Low premobilization BM cellularityHosing et al., 2009 [84]
Olivieri et al., 2012 [87]

Low baseline CD34+ cell countFruehauf et al., 1999 [68]
Han et al., 2012 [98]
Fu et al., 2006 [99]

Low platelet count before mobilizationFruehauf et al., 1999 [68]
Hosing et al., 2009 [84]
Wuchter et al., 2010 [86]
Han et al., 2012 [98]
Suzuya et al., 2005 [100]
Zubair et al., 2008 [101]

G-CSF: granulocyte colony-stimulating factor.
BM: bone marrow.
Myelotoxic chemotherapy: melphalan, carmustine, dacarbazine, fludarabine, lenalidomide, platinum compounds.